nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—Depression—Mechlorethamine—lymphatic system cancer	0.0181	0.0181	CcSEcCtD
Roflumilast—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.0152	0.0152	CcSEcCtD
Roflumilast—Vertigo—Mechlorethamine—lymphatic system cancer	0.0127	0.0127	CcSEcCtD
Roflumilast—Gynaecomastia—Carmustine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.012	0.012	CcSEcCtD
Roflumilast—Pneumonia—Fludarabine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Roflumilast—Infection—Mechlorethamine—lymphatic system cancer	0.0115	0.0115	CcSEcCtD
Roflumilast—Urinary tract infection—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Roflumilast—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0112	0.0112	CcSEcCtD
Roflumilast—Sinusitis—Fludarabine—lymphatic system cancer	0.011	0.011	CcSEcCtD
Roflumilast—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Roflumilast—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00984	0.00984	CcSEcCtD
Roflumilast—Malnutrition—Fludarabine—lymphatic system cancer	0.00919	0.00919	CcSEcCtD
Roflumilast—Weight decreased—Bleomycin—lymphatic system cancer	0.00875	0.00875	CcSEcCtD
Roflumilast—Pneumonia—Bleomycin—lymphatic system cancer	0.00867	0.00867	CcSEcCtD
Roflumilast—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Roflumilast—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00853	0.00853	CcSEcCtD
Roflumilast—Infection—Teniposide—lymphatic system cancer	0.00848	0.00848	CcSEcCtD
Roflumilast—Malaise—Fludarabine—lymphatic system cancer	0.00829	0.00829	CcSEcCtD
Roflumilast—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00792	0.00792	CcSEcCtD
Roflumilast—Myalgia—Fludarabine—lymphatic system cancer	0.00783	0.00783	CcSEcCtD
Roflumilast—Discomfort—Fludarabine—lymphatic system cancer	0.00773	0.00773	CcSEcCtD
Roflumilast—Pneumonia—Carmustine—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Roflumilast—Depression—Carmustine—lymphatic system cancer	0.00751	0.00751	CcSEcCtD
Roflumilast—Infection—Fludarabine—lymphatic system cancer	0.00745	0.00745	CcSEcCtD
Roflumilast—Decreased appetite—Teniposide—lymphatic system cancer	0.00742	0.00742	CcSEcCtD
Roflumilast—Vomiting—Mechlorethamine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Roflumilast—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00736	0.00736	CcSEcCtD
Roflumilast—Urinary tract infection—Carmustine—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Roflumilast—Rash—Mechlorethamine—lymphatic system cancer	0.0073	0.0073	CcSEcCtD
Roflumilast—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Roflumilast—Weight decreased—Vincristine—lymphatic system cancer	0.00729	0.00729	CcSEcCtD
Roflumilast—Pneumonia—Vincristine—lymphatic system cancer	0.00723	0.00723	CcSEcCtD
Roflumilast—Depression—Vincristine—lymphatic system cancer	0.00717	0.00717	CcSEcCtD
Roflumilast—Weight decreased—Mitoxantrone—lymphatic system cancer	0.0071	0.0071	CcSEcCtD
Roflumilast—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00704	0.00704	CcSEcCtD
Roflumilast—Feeling abnormal—Teniposide—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Roflumilast—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00698	0.00698	CcSEcCtD
Roflumilast—Nausea—Mechlorethamine—lymphatic system cancer	0.00688	0.00688	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00683	0.00683	CcSEcCtD
Roflumilast—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.0068	0.0068	CcSEcCtD
Roflumilast—Urticaria—Teniposide—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Roflumilast—Abdominal pain—Teniposide—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Roflumilast—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00664	0.00664	CcSEcCtD
Roflumilast—Dyspepsia—Fludarabine—lymphatic system cancer	0.0066	0.0066	CcSEcCtD
Roflumilast—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00657	0.00657	CcSEcCtD
Roflumilast—Decreased appetite—Fludarabine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00648	0.00648	CcSEcCtD
Roflumilast—Fatigue—Fludarabine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Roflumilast—Constipation—Fludarabine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Roflumilast—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00634	0.00634	CcSEcCtD
Roflumilast—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Roflumilast—Hypersensitivity—Teniposide—lymphatic system cancer	0.00629	0.00629	CcSEcCtD
Roflumilast—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Roflumilast—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00618	0.00618	CcSEcCtD
Roflumilast—Asthenia—Teniposide—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Roflumilast—Malaise—Bleomycin—lymphatic system cancer	0.00608	0.00608	CcSEcCtD
Roflumilast—Cardiac disorder—Vincristine—lymphatic system cancer	0.00599	0.00599	CcSEcCtD
Roflumilast—Mental disorder—Carmustine—lymphatic system cancer	0.00592	0.00592	CcSEcCtD
Roflumilast—Malnutrition—Carmustine—lymphatic system cancer	0.00588	0.00588	CcSEcCtD
Roflumilast—Diarrhoea—Teniposide—lymphatic system cancer	0.00584	0.00584	CcSEcCtD
Roflumilast—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00581	0.00581	CcSEcCtD
Roflumilast—Myalgia—Bleomycin—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Roflumilast—Back pain—Carmustine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Roflumilast—Discomfort—Bleomycin—lymphatic system cancer	0.00567	0.00567	CcSEcCtD
Roflumilast—Mental disorder—Vincristine—lymphatic system cancer	0.00565	0.00565	CcSEcCtD
Roflumilast—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Roflumilast—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00553	0.00553	CcSEcCtD
Roflumilast—Tremor—Carmustine—lymphatic system cancer	0.00551	0.00551	CcSEcCtD
Roflumilast—Infection—Bleomycin—lymphatic system cancer	0.00546	0.00546	CcSEcCtD
Roflumilast—Back pain—Vincristine—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Roflumilast—Vomiting—Teniposide—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Roflumilast—Asthenia—Fludarabine—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Roflumilast—Rash—Teniposide—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Roflumilast—Dermatitis—Teniposide—lymphatic system cancer	0.00538	0.00538	CcSEcCtD
Roflumilast—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00536	0.00536	CcSEcCtD
Roflumilast—Headache—Teniposide—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Roflumilast—Back pain—Mitoxantrone—lymphatic system cancer	0.00529	0.00529	CcSEcCtD
Roflumilast—Diarrhoea—Fludarabine—lymphatic system cancer	0.00513	0.00513	CcSEcCtD
Roflumilast—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Roflumilast—Nausea—Teniposide—lymphatic system cancer	0.00507	0.00507	CcSEcCtD
Roflumilast—Vertigo—Vincristine—lymphatic system cancer	0.00505	0.00505	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Roflumilast—Myalgia—Carmustine—lymphatic system cancer	0.00501	0.00501	CcSEcCtD
Roflumilast—Anxiety—Carmustine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Roflumilast—Malaise—Mitoxantrone—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Roflumilast—Renal failure acute—Methotrexate—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Roflumilast—Decreased appetite—Bleomycin—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Roflumilast—Myalgia—Vincristine—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Roflumilast—Infection—Carmustine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Roflumilast—Vomiting—Fludarabine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Roflumilast—Rash—Fludarabine—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Roflumilast—Dermatitis—Fludarabine—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Roflumilast—Headache—Fludarabine—lymphatic system cancer	0.0047	0.0047	CcSEcCtD
Roflumilast—Myalgia—Mitoxantrone—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Roflumilast—Anxiety—Mitoxantrone—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Roflumilast—Discomfort—Mitoxantrone—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Roflumilast—Infection—Vincristine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Roflumilast—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00453	0.00453	CcSEcCtD
Roflumilast—Nervous system disorder—Vincristine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Roflumilast—Nausea—Fludarabine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Roflumilast—Infection—Mitoxantrone—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Roflumilast—Urticaria—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Roflumilast—Insomnia—Carmustine—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Roflumilast—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Roflumilast—Decreased appetite—Carmustine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Roflumilast—Insomnia—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Roflumilast—Constipation—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Roflumilast—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Roflumilast—Decreased appetite—Vincristine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Roflumilast—Feeling abnormal—Carmustine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Roflumilast—Fatigue—Vincristine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Roflumilast—Asthenia—Bleomycin—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Roflumilast—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Roflumilast—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Roflumilast—Constipation—Vincristine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Roflumilast—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Roflumilast—Fatigue—Mitoxantrone—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Roflumilast—Constipation—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Roflumilast—Abdominal pain—Carmustine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Roflumilast—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Roflumilast—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Roflumilast—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Roflumilast—Abdominal pain—Vincristine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Roflumilast—Urticaria—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Roflumilast—Hypersensitivity—Carmustine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Roflumilast—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Roflumilast—Pneumonia—Methotrexate—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Roflumilast—Vomiting—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Roflumilast—Infestation NOS—Methotrexate—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Roflumilast—Infestation—Methotrexate—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Roflumilast—Depression—Methotrexate—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Roflumilast—Rash—Bleomycin—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Roflumilast—Dermatitis—Bleomycin—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Roflumilast—Asthenia—Carmustine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Roflumilast—Hypersensitivity—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Roflumilast—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Roflumilast—Asthenia—Vincristine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Roflumilast—Diarrhoea—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Roflumilast—Nausea—Bleomycin—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Roflumilast—Asthenia—Mitoxantrone—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Roflumilast—Dizziness—Carmustine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Roflumilast—Diarrhoea—Vincristine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Roflumilast—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Roflumilast—Vomiting—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Roflumilast—Dizziness—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Roflumilast—Rash—Carmustine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Roflumilast—Dermatitis—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Roflumilast—Headache—Carmustine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Roflumilast—Vomiting—Vincristine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Roflumilast—Rash—Vincristine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Roflumilast—Dermatitis—Vincristine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Roflumilast—Headache—Vincristine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Roflumilast—Nausea—Carmustine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Roflumilast—Vomiting—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Roflumilast—Rash—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Roflumilast—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Roflumilast—Headache—Mitoxantrone—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Roflumilast—Nausea—Vincristine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Roflumilast—Nausea—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Roflumilast—Back pain—Methotrexate—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Roflumilast—Malaise—Methotrexate—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Roflumilast—Infection—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Roflumilast—Rash—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Roflumilast—Headache—Methotrexate—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Roflumilast—Nausea—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
